Mersana Therapeutics Inc (MRSN) Stock Price, Quote & News

Latest News on MRSN

Apr 23, 2025, 10:12 AM EDT - 3 days ago

Mersana Therapeutics Announces Upcoming Emi-Le Oral and Poster Presentations at ASCO 2025 Annual Meeting

Apr 4, 2025, 4:05 PM EDT - 22 days ago

Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apr 1, 2025, 8:01 AM EDT - 25 days ago

Mersana Therapeutics Announces Upcoming Oral Presentation of Emi-Le Clinical Data at European Society for Medical Oncology (ESMO) Breast Cancer 2025 Annual Congress

Mar 3, 2025, 10:13 AM EST - 7 weeks ago

Mersana Therapeutics, Inc. (MRSN) Q4 2024 Earnings Call Transcript

Mar 3, 2025, 7:01 AM EST - 7 weeks ago

Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial Results

Feb 25, 2025, 8:00 AM EST - 2 months ago

Mersana Therapeutics to Present at Upcoming Investor Conferences

Feb 24, 2025, 4:01 PM EST - 2 months ago

Mersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025

Jan 30, 2025, 8:00 AM EST - 3 months ago

Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

Jan 10, 2025, 12:49 PM EST - 3 months ago

Why Is Cancer-Focused Mersana Therapeutics Stock Trading Lower On Friday?

Jan 10, 2025, 6:02 AM EST - 3 months ago

Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)

Jan 10, 2025, 6:00 AM EST - 3 months ago

Mersana Therapeutics Announces Positive Initial Clinical Data from Phase 1 Clinical Trial of Emiltatug Ledadotin (XMT-1660); Initiation of Expansion in Triple Negative Breast Cancer

Dec 19, 2024, 7:17 AM EST - 4 months ago

Mersana Therapeutics: We're About To Find Out If ADC Platform Is More Tolerable

Nov 13, 2024, 1:26 PM EST - 5 months ago

Mersana Therapeutics, Inc. (MRSN) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 7:00 AM EST - 5 months ago

Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results

Nov 6, 2024, 8:00 AM EST - 6 months ago

Mersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024

Aug 13, 2024, 12:55 PM EDT - 9 months ago

Mersana Therapeutics, Inc. (MRSN) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 7:00 AM EDT - 9 months ago

Mersana Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results

Aug 6, 2024, 8:00 AM EDT - 9 months ago

Mersana Therapeutics to Host Second Quarter 2024 Conference Call on August 13, 2024

May 9, 2024, 2:09 PM EDT - 1 year ago

Mersana Therapeutics, Inc. (MRSN) Q1 2024 Earnings Call Transcript

May 9, 2024, 6:59 AM EDT - 1 year ago

Mersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results

May 3, 2024, 4:30 PM EDT - 1 year ago

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 2, 2024, 8:00 AM EDT - 1 year ago

Mersana Therapeutics to Host First Quarter 2024 Conference Call on May 9, 2024

Feb 28, 2024, 2:10 PM EST - 1 year ago

Mersana Therapeutics, Inc. (MRSN) Q4 2023 Earnings Call Transcript

Feb 28, 2024, 7:00 AM EST - 1 year ago

Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results

Feb 21, 2024, 8:00 AM EST - 1 year ago

Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024

Feb 1, 2024, 8:00 AM EST - 1 year ago

Mersana Therapeutics to Participate in Guggenheim's 6th Annual Biotechnology Conference

Jan 5, 2024, 8:01 AM EST - 1 year ago

Mersana Therapeutics Announces Business Updates, Expected 2024 Milestones and Upcoming Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 7, 2023, 1:34 PM EST - 1 year ago

Mersana Therapeutics, Inc. (MRSN) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 7:00 AM EST - 1 year ago

Mersana Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results

Oct 31, 2023, 4:30 PM EDT - 1 year ago

Mersana Therapeutics to Host Third Quarter 2023 Conference Call on November 7, 2023

Oct 31, 2023, 8:00 AM EDT - 1 year ago

Mersana Therapeutics Announces FDA has Lifted Clinical Hold on Phase 1 Clinical Trial of XMT-2056

Sep 6, 2023, 7:00 AM EDT - 1 year ago

Mersana Therapeutics Announces Changes in Leadership

Aug 8, 2023, 8:00 AM EDT - 1 year ago

Mersana Therapeutics Announces Second Quarter 2023 Financial Results

Jul 27, 2023, 7:06 AM EDT - 1 year ago

Mersana Therapeutics Announces Topline Data from UPLIFT Clinical Trial in Patients with Platinum-Resistant Ovarian Cancer and Strategic Reprioritization

Jun 27, 2023, 5:45 AM EDT - 1 year ago

MRSN NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Mersana Therapeutics, Inc.

Jun 15, 2023, 8:03 AM EDT - 2 years ago

US FDA puts Mersana Therapeutics' ovarian cancer drug studies on partial hold

Jun 15, 2023, 8:00 AM EDT - 2 years ago

Mersana Therapeutics stock craters after FDA halts trials of ovarian cancer treatment after bleeding events

Jun 15, 2023, 7:30 AM EDT - 2 years ago

Mersana Therapeutics Announces Partial Clinical Hold on UP-NEXT and UPGRADE-A Clinical Trials

May 9, 2023, 1:45 PM EDT - 2 years ago

Mersana Therapeutics, Inc. (MRSN) Q1 2023 Earnings Call Transcript

May 9, 2023, 7:00 AM EDT - 2 years ago

Mersana Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results

May 3, 2023, 8:00 AM EDT - 2 years ago

Mersana Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference

May 2, 2023, 8:00 AM EDT - 2 years ago

Mersana Therapeutics to Host First Quarter 2023 Conference Call on May 9, 2023

Apr 26, 2023, 4:05 PM EDT - 2 years ago

Mersana Therapeutics Announces Upcoming Presentations at 2023 ASCO Annual Meeting

Apr 3, 2023, 5:20 PM EDT - 2 years ago

Mersana Therapeutics: Unrecognized Promise In UpRi's Cancer Fight

Mar 13, 2023, 7:30 AM EDT - 2 years ago

Market Cap	45.35M
Revenue (ttm)	40.50M
Net Income (ttm)	-69.19M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-170.84%
Debt to Equity Ratio	-2.47

Volume	1,687,000
Avg Vol	3,260,968
Day's Range	N/A - N/A
Shares Out	124.63M
Stochastic %K	45%
Beta	1.68
Analysts	Strong Sell
Price Target	$5.00